Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Graceway Pharmaceuticals has received the US Food and Drug Administration (FDA)approval for Zyclara cream to treat external genital and perianal warts (EGW) in patients 12 years of age and older.
Subscribe to our email newsletter
In clinical studies, Zyclara cream cleared genital warts safely and effectively in about eight weeks.
In addition, data showed that of those patients who achieved complete clearance, only a small number experienced a recurrence of their wart(s) 12 weeks after treatment.
Graceway Pharma chairman and CEO Jefferson Gregory said many of the currently approved topical treatments for genital warts are not ideal due to lengthy and confusing dosing regimens.
"Our vision for Zyclara Cream is to improve the patient experience by offering a more intuitive dosing regimen (once daily treatment for up to eight weeks) with the goal of improving patient compliance," Gregory said.